Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IFInflaRx N.V. logo

InflaRx N.V. (IFRX)

NASDAQ Global Select · Currency in USD
$1.56 ▲ +0.03 (+1.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.56 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.53
Open
$1.49
Day's Range
$1.49 – $1.58
52 Week Range
$0.80 – $2.95
Volume
889,582
Avg. Volume
930,848
Market Cap
$229.89M
Beta (5Y Monthly)
2.61
PE Ratio (TTM)
--
EPS (TTM)
-$0.33
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.00

Profile: InflaRx N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
65
CEO
Niels C. Riedemann
Website
inflarx.de

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.07 · Revenue est. $6.07K
DateEst.Actual
Aug 6, 2026-$0.07-$0.11Miss
May 7, 2026-$0.17-$0.09Beat
Mar 19, 2026-$0.18-$0.17Beat
Nov 10, 2025-$0.16-$0.16Beat
Aug 7, 2025-$0.24-$0.24Beat
May 7, 2025-$0.18-$0.14Beat

Analyst view

Consensus price target
$9.00 ▲ +476.9%
Range $9.00 – $9.00
Rating: Buy
Buy 81% · Hold 13% · Sell 6%

Get free alerts on IFRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.